share_log

Ladenburg Thalmann Initiates Coverage On Corvus Pharmaceuticals With Buy Rating, Announces Price Target of $2

Ladenburg Thalmann Initiates Coverage On Corvus Pharmaceuticals With Buy Rating, Announces Price Target of $2

拉登堡塔爾曼以買入評級啓動對Corvus Pharmicals的報道,宣佈目標股價爲2美元
Benzinga Real-time News ·  2022/10/07 08:41

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy rating and announces Price Target of $2.

拉登堡·塔爾曼分析師艾登·侯賽諾夫以買入評級開始對Corvus Pharmicals(納斯達克股票代碼:CRVS)進行報道,並宣佈目標股價爲2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論